ReviewCureus2026
Pregnancy Outcomes in Women With Vascular Ehlers-Danlos Syndrome: A Systematic Review of Maternal and Fetal Complications.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Ehlers-Danlos syndromes (EDS) comprise a clinically and genetically heterogeneous group of heritable connective tissue disorders marked by skin hyperextensibility, joint hypermobility, and tissue fragility. Vascular EDS (vEDS) is an autosomal dominant disorder caused by pathogenic variants in COL3A1, the gene encoding type III collagen. The diagnosis of vEDS is confirmed by identifying a pathogenic variant in COL3A1. This systematic review was conducted according to the PRISMA guidelines. Major outcomes included maternal, fetal, and neonatal complications in EDS pregnancies. A comprehensive search was conducted using electronic databases, including PubMed, Cochrane Library, and ScienceDirect, from inception to April 2026. vEDS showed the highest risk profile, with maternal mortality ranging between 0.10% and 50%; however, this wide range is attributed to the inclusion of old studies, in which recent advancements in genetic testing and fetal genotyping were not used. The most common reported obstetric complications were preeclampsia, postpartum hemorrhage, and severe perineal tears. Premature rupture of membranes and preterm premature rupture of membranes were strongly associated with fetal EDS. Preterm birth is the most common complication, ranging between 8.9% and 48.8% of pregnancies across the included studies. Fetal EDS and COL3A1 mutations were more commonly associated with pregnancy complications than the maternal disease itself. Pregnancies complicated by EDS are associated with maternal, fetal, and neonatal complications. vEDS is associated with an increased risk of maternal mortality and a high prevalence of preterm birth. This systematic review underscores the significance of fetal EDS status and COL3A1 variants as a strong predictor of EDS pregnancy complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.